The evolution of non-small cell lung cancer metastases in TRACERx.


Journal

Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462

Informations de publication

Date de publication:
04 2023
Historique:
received: 21 10 2021
accepted: 12 01 2023
medline: 21 4 2023
pubmed: 13 4 2023
entrez: 12 4 2023
Statut: ppublish

Résumé

Metastatic disease is responsible for the majority of cancer-related deaths

Identifiants

pubmed: 37046095
doi: 10.1038/s41586-023-05729-x
pii: 10.1038/s41586-023-05729-x
pmc: PMC10115651
doi:

Banques de données

ClinicalTrials.gov
['NCT01888601']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

534-542

Subventions

Organisme : Cancer Research UK
ID : 25354
Pays : United Kingdom
Organisme : Cancer Research UK
ID : CTRNBC-2022/100001
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 25349
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 21999
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 24956
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 17786
Pays : United Kingdom
Organisme : Arthritis Research UK
ID : CC2008
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/V033077/1
Pays : United Kingdom
Organisme : Arthritis Research UK
ID : CC2041
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 29569
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 30025
Pays : United Kingdom

Investigateurs

Jason F Lester (JF)
Amrita Bajaj (A)
Apostolos Nakas (A)
Azmina Sodha-Ramdeen (A)
Keng Ang (K)
Mohamad Tufail (M)
Mohammed Fiyaz Chowdhry (MF)
Molly Scotland (M)
Rebecca Boyles (R)
Sridhar Rathinam (S)
Claire Wilson (C)
Domenic Marrone (D)
Sean Dulloo (S)
Gurdeep Matharu (G)
Jacqui A Shaw (JA)
Joan Riley (J)
Lindsay Primrose (L)
Ekaterini Boleti (E)
Heather Cheyne (H)
Mohammed Khalil (M)
Shirley Richardson (S)
Tracey Cruickshank (T)
Sarah Benafif (S)
Kayleigh Gilbert (K)
Akshay J Patel (AJ)
Aya Osman (A)
Christer Lacson (C)
Gerald Langman (G)
Helen Shackleford (H)
Madava Djearaman (M)
Salma Kadiri (S)
Angela Leek (A)
Jack Davies Hodgkinson (JD)
Nicola Totten (N)
Angeles Montero (A)
Elaine Smith (E)
Eustace Fontaine (E)
Felice Granato (F)
Helen Doran (H)
Juliette Novasio (J)
Kendadai Rammohan (K)
Leena Joseph (L)
Paul Bishop (P)
Rajesh Shah (R)
Stuart Moss (S)
Vijay Joshi (V)
Philip Crosbie (P)
Fabio Gomes (F)
Kate Brown (K)
Mathew Carter (M)
Anshuman Chaturvedi (A)
Lynsey Priest (L)
Pedro Oliveira (P)
Matthew G Krebs (MG)
Alexandra Clipson (A)
Jonathan Tugwood (J)
Alastair Kerr (A)
Dominic G Rothwell (DG)
Elaine Kilgour (E)
Hugo J W L Aerts (HJWL)
Roland F Schwarz (RF)
Tom L Kaufmann (TL)
Rachel Rosenthal (R)
Zoltan Szallasi (Z)
Judit Kisistok (J)
Mateo Sokac (M)
Miklos Diossy (M)
Jonas Demeulemeester (J)
Aengus Stewart (A)
Alastair Magness (A)
Angeliki Karamani (A)
Benny Chain (B)
Brittany B Campbell (BB)
Carla Castignani (C)
Chris Bailey (C)
Clare Puttick (C)
Clare E Weeden (CE)
Claudia Lee (C)
Corentin Richard (C)
David R Pearce (DR)
Despoina Karagianni (D)
Dhruva Biswas (D)
Dina Levi (D)
Elena Hoxha (E)
Elizabeth Larose Cadieux (E)
Eva Grönroos (E)
Felip Gálvez-Cancino (F)
Foteini Athanasopoulou (F)
Francisco Gimeno-Valiente (F)
George Kassiotis (G)
Georgia Stavrou (G)
Gerasimos Mastrokalos (G)
Haoran Zhai (H)
Helen L Lowe (HL)
Ignacio Matos (I)
Jacki Goldman (J)
James L Reading (JL)
James R M Black (JRM)
Javier Herrero (J)
Jayant K Rane (JK)
Jerome Nicod (J)
Jie Min Lam (JM)
John A Hartley (JA)
Katey S S Enfield (KSS)
Kayalvizhi Selvaraju (K)
Kerstin Thol (K)
Kevin Litchfield (K)
Kevin W Ng (KW)
Kezhong Chen (K)
Krijn Dijkstra (K)
Krupa Thakkar (K)
Leah Ensell (L)
Mansi Shah (M)
Marcos Vasquez (M)
Maria Litovchenko (M)
Mariana Werner Sunderland (M)
Michelle Leung (M)
Mickael Escudero (M)
Mihaela Angelova (M)
Miljana Tanić (M)
Monica Sivakumar (M)
Nnennaya Kanu (N)
Olga Chervova (O)
Olivia Lucas (O)
Othman Al-Sawaf (O)
Philip Hobson (P)
Piotr Pawlik (P)
Robert Bentham (R)
Robert E Hynds (RE)
Roberto Vendramin (R)
Sadegh Saghafinia (S)
Saioa López (S)
Samuel Gamble (S)
Seng Kuong Anakin Ung (SKA)
Sharon Vanloo (S)
Stefan Boeing (S)
Stephan Beck (S)
Supreet Kaur Bola (SK)
Tamara Denner (T)
Teresa Marafioti (T)
Thanos P Mourikis (TP)
Victoria Spanswick (V)
Vittorio Barbè (V)
Wei-Ting Lu (WT)
William Hill (W)
Wing Kin Liu (WK)
Yin Wu (Y)
Yutaka Naito (Y)
Zoe Ramsden (Z)
Catarina Veiga (C)
Gary Royle (G)
Charles-Antoine Collins-Fekete (CA)
Francesco Fraioli (F)
Paul Ashford (P)
Tristan Clark (T)
Elaine Borg (E)
James Wilson (J)
Davide Patrini (D)
Emilie Martinoni Hoogenboom (E)
Fleur Monk (F)
James W Holding (JW)
Junaid Choudhary (J)
Kunal Bhakhri (K)
Marco Scarci (M)
Martin Hayward (M)
Nikolaos Panagiotopoulos (N)
Pat Gorman (P)
Reena Khiroya (R)
Robert C M Stephens (RCM)
Yien Ning Sophia Wong (YNS)
Steve Bandula (S)
Abigail Sharp (A)
Sean Smith (S)
Nicole Gower (N)
Harjot Kaur Dhanda (HK)
Kitty Chan (K)
Camilla Pilotti (C)
Rachel Leslie (R)
Anca Grapa (A)
Hanyun Zhang (H)
Khalid AbdulJabbar (K)
Xiaoxi Pan (X)
Yinyin Yuan (Y)
David Chuter (D)
Mairead MacKenzie (M)
Serena Chee (S)
Aiman Alzetani (A)
Lydia Scarlett (L)
Jennifer Richards (J)
Papawadee Ingram (P)
Silvia Austin (S)
Eric Lim (E)
Paulo De Sousa (P)
Simon Jordan (S)
Alexandra Rice (A)
Hilgardt Raubenheimer (H)
Harshil Bhayani (H)
Lyn Ambrose (L)
Anand Devaraj (A)
Hema Chavan (H)
Sofina Begum (S)
Silviu I Buderi (SI)
Daniel Kaniu (D)
Mpho Malima (M)
Sarah Booth (S)
Andrew G Nicholson (AG)
Nadia Fernandes (N)
Pratibha Shah (P)
Chiara Proli (C)
Madeleine Hewish (M)
Sarah Danson (S)
Michael J Shackcloth (MJ)
Lily Robinson (L)
Peter Russell (P)
Craig Dick (C)
John Le Quesne (J)
Alan Kirk (A)
Mo Asif (M)
Rocco Bilancia (R)
Nikos Kostoulas (N)
Mathew Thomas (M)

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2023. The Author(s).

Références

Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424 (2018).
pubmed: 30207593 doi: 10.3322/caac.21492
Zappa, C. & Mousa, S. A. Non-small cell lung cancer: current treatment and future advances. Transl. Lung Cancer Res. 5, 288–300 (2016).
pubmed: 27413711 pmcid: 4931124 doi: 10.21037/tlcr.2016.06.07
Jamal-Hanjani, M. et al. Tracking the evolution of non–small-cell lung cancer. N. Engl. J. Med. 376, 2109–2121 (2017).
pubmed: 28445112 doi: 10.1056/NEJMoa1616288
Grigoriadis, K. et al. CONIPHER: a computational framework for scalable phylogenetic reconstruction with error correction. Protoc. Exchange https://doi.org/10.21203/rs.3.pex-2158/v1 (2023).
de Bruin, E. C. et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 346, 251–256 (2014).
pubmed: 25301630 pmcid: 4636050 doi: 10.1126/science.1253462
Pich, O. et al. The mutational footprints of cancer therapies. Nat. Genet. 51, 1732–1740 (2019).
pubmed: 31740835 pmcid: 6887544 doi: 10.1038/s41588-019-0525-5
Landau, H. J. et al. Accelerated single cell seeding in relapsed multiple myeloma. Nat. Commun. 11, 3617 (2020).
pubmed: 32680998 pmcid: 7368016 doi: 10.1038/s41467-020-17459-z
Pich, O. et al. The evolution of hematopoietic cells under cancer therapy. Nat. Commun. 12, 4803 (2021).
pubmed: 34376657 pmcid: 8355079 doi: 10.1038/s41467-021-24858-3
Sun, R. et al. Between-region genetic divergence reflects the mode and tempo of tumor evolution. Nat. Genet. 49, 1015–1024 (2017).
pubmed: 28581503 pmcid: 5643198 doi: 10.1038/ng.3891
Bueno, J., Landeras, L. & Chung, J. H. Updated Fleischner society guidelines for managing incidental pulmonary nodules: common questions and challenging scenarios. Radiographics 38, 1337–1350 (2018).
pubmed: 30207935 doi: 10.1148/rg.2018180017
Callister, M. E. J. et al. British Thoracic Society guidelines for the investigation and management of pulmonary nodules. Thorax 70, ii1–ii54 (2015).
pubmed: 26082159 doi: 10.1136/thoraxjnl-2015-207168
Horeweg, N. et al. Lung cancer probability in patients with CT-detected pulmonary nodules: a prespecified analysis of data from the NELSON trial of low-dose CT screening. Lancet Oncol. 15, 1332–1341 (2014).
pubmed: 25282285 doi: 10.1016/S1470-2045(14)70389-4
de Koning, H. J. et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. N. Engl. J. Med. 382, 503–513 (2020).
pubmed: 31995683 doi: 10.1056/NEJMoa1911793
Oudkerk, M. et al. European position statement on lung cancer screening. Lancet Oncol. 18, e754–e766 (2017).
pubmed: 29208441 doi: 10.1016/S1470-2045(17)30861-6
MacMahon, H. et al. Guidelines for management of incidental pulmonary nodules detected on CT images: from the Fleischner Society 2017. Radiology 284, 228–243 (2017).
pubmed: 28240562 doi: 10.1148/radiol.2017161659
American College of Radiology Committee on Lung-RADS. Lung-RADS Assessment Categories version 1.1 (ACR, 2019); https://www.acr.org/-/media/ACR/Files/RADS/Lung-RADS/LungRADSAssessmentCategoriesv1-1.pdf.
Frankell, A. M. et al. The evolution of lung cancer and impact of subclonal selection in TRACERx. Nature https://doi.org/10.1038/s41586-023-05783-5 (2023).
El-Kebir, M., Satas, G. & Raphael, B. J. Inferring parsimonious migration histories for metastatic cancers. Nat. Genet. 50, 718–726 (2018).
pubmed: 29700472 pmcid: 6103651 doi: 10.1038/s41588-018-0106-z
Abbosh, C. et al. Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA. Nature https://doi.org/10.1038/s41586-023-05776-4 (2023).
Martincorena, I. et al. Universal patterns of selection in cancer and somatic tissues. Cell 171, 1029–1041 (2017).
pubmed: 29056346 pmcid: 5720395 doi: 10.1016/j.cell.2017.09.042
Bailey, M. H. et al. Comprehensive characterization of cancer driver genes and mutations. Cell 174, 1034–1035 (2018).
pubmed: 30096302 pmcid: 8045146 doi: 10.1016/j.cell.2018.07.034
Mermel, C. H. et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 12, R41 (2011).
pubmed: 21527027 pmcid: 3218867 doi: 10.1186/gb-2011-12-4-r41
Lee, W.-C. et al. Multiomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity. Genome Biol. 21, 271 (2020).
pubmed: 33148332 pmcid: 7640699 doi: 10.1186/s13059-020-02175-0
Brown, D. et al. Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations. Nat. Commun. 8, 14944 (2017).
pubmed: 28429735 pmcid: 5474888 doi: 10.1038/ncomms14944
Faltas, B. M. et al. Clonal evolution of chemotherapy-resistant urothelial carcinoma. Nat. Genet. 48, 1490–1499 (2016).
pubmed: 27749842 pmcid: 5549141 doi: 10.1038/ng.3692
Hu, Z. et al. Quantitative evidence for early metastatic seeding in colorectal cancer. Nat. Genet. 51, 1113–1122 (2019).
pubmed: 31209394 pmcid: 6982526 doi: 10.1038/s41588-019-0423-x
Naxerova, K. et al. Origins of lymphatic and distant metastases in human colorectal cancer. Science 357, 55–60 (2017).
pubmed: 28684519 pmcid: 5536201 doi: 10.1126/science.aai8515
Kim, T.-M. et al. Subclonal genomic architectures of primary and metastatic colorectal cancer based on intratumoral genetic heterogeneity. Clin. Cancer Res. 21, 4461–4472 (2015).
pubmed: 25979483 doi: 10.1158/1078-0432.CCR-14-2413
Zhao, Z.-M. et al. Early and multiple origins of metastatic lineages within primary tumors. Proc. Natl Acad. Sci. USA 113, 2140–2145 (2016).
pubmed: 26858460 pmcid: 4776530 doi: 10.1073/pnas.1525677113
Zhai, W. et al. The spatial organization of intra-tumour heterogeneity and evolutionary trajectories of metastases in hepatocellular carcinoma. Nat. Commun. 8, 4565 (2017).
pubmed: 28240289 pmcid: 5333358 doi: 10.1038/ncomms14565
Gibson, W. J. et al. The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis. Nat. Genet. 48, 848–855 (2016).
pubmed: 27348297 pmcid: 4963271 doi: 10.1038/ng.3602
Reiter, J. G. et al. Lymph node metastases develop through a wider evolutionary bottleneck than distant metastases. Nat. Genet. 52, 692–700 (2020).
pubmed: 32451459 pmcid: 7343611 doi: 10.1038/s41588-020-0633-2
Tang, W.-F. et al. Timing and origins of local and distant metastases in lung cancer. J. Thorac. Oncol. 16, 1136–1148 (2021).
pubmed: 33722707 doi: 10.1016/j.jtho.2021.02.023
Tan, Q. et al. Genomic alteration during metastasis of lung adenocarcinoma. Cell. Physiol. Biochem. 38, 469–486 (2016).
pubmed: 26828653 doi: 10.1159/000438644
Hu, Z., Li, Z., Ma, Z. & Curtis, C. Multi-cancer analysis of clonality and the timing of systemic spread in paired primary tumors and metastases. Nat. Genet. 52, 701–708 (2020).
pubmed: 32424352 pmcid: 7343625 doi: 10.1038/s41588-020-0628-z
Ullah, I. et al. Evolutionary history of metastatic breast cancer reveals minimal seeding from axillary lymph nodes. J. Clin. Invest. 128, 1355–1370 (2018).
pubmed: 29480816 pmcid: 5873882 doi: 10.1172/JCI96149
Haffner, M. C. et al. Tracking the clonal origin of lethal prostate cancer. J. Clin. Invest. 123, 4918–4922 (2013).
pubmed: 24135135 pmcid: 3809798 doi: 10.1172/JCI70354
Noorani, A. et al. Genomic evidence supports a clonal diaspora model for metastases of esophageal adenocarcinoma. Nat. Genet. 52, 74–83 (2020).
pubmed: 31907488 pmcid: 7100916 doi: 10.1038/s41588-019-0551-3
Gundem, G. et al. The evolutionary history of lethal metastatic prostate cancer. Nature 520, 353–357 (2015).
pubmed: 25830880 pmcid: 4413032 doi: 10.1038/nature14347
Chen, H.-N. et al. Genomic evolution and diverse models of systemic metastases in colorectal cancer. Gut 71, 322–332 (2022).
pubmed: 33632712 doi: 10.1136/gutjnl-2020-323703
Abbosh, C. et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature 545, 446–451 (2017).
pubmed: 28445469 pmcid: 5812436 doi: 10.1038/nature22364
Turajlic, S. et al. Tracking cancer evolution reveals constrained routes to metastases: TRACERx renal. Cell 173, 581–594 (2018).
pubmed: 29656895 pmcid: 5938365 doi: 10.1016/j.cell.2018.03.057
Bailey, C. et al. Tracking cancer evolution through the disease course. Cancer Discov. 11, 916–932 (2021).
pubmed: 33811124 pmcid: 7611362 doi: 10.1158/2159-8290.CD-20-1559
Rosenthal, R., McGranahan, N., Herrero, J., Taylor, B. S. & Swanton, C. DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. Genome Biol. 17, 31 (2016).
pubmed: 26899170 pmcid: 4762164 doi: 10.1186/s13059-016-0893-4
Alexandrov, L. B. et al. The repertoire of mutational signatures in human cancer. Nature 578, 94–101 (2020).
pubmed: 32025018 pmcid: 7054213 doi: 10.1038/s41586-020-1943-3
Boot, A. et al. In-depth characterization of the cisplatin mutational signature in human cell lines and in esophageal and liver tumors. Genome Res. 28, 654–665 (2018).
pubmed: 29632087 pmcid: 5932606 doi: 10.1101/gr.230219.117
Sottoriva, A. et al. A Big Bang model of human colorectal tumor growth. Nat. Genet. 47, 209–216 (2015).
pubmed: 25665006 pmcid: 4575589 doi: 10.1038/ng.3214
Cannataro, V. L., McKinley, S. A. & St Mary, C. M. The implications of small stem cell niche sizes and the distribution of fitness effects of new mutations in aging and tumorigenesis. Evol. Appl. 9, 565–582 (2016).
pubmed: 27099622 pmcid: 4831459 doi: 10.1111/eva.12361
Lebeuf-Taylor, E., McCloskey, N., Bailey, S. F., Hinz, A. & Kassen, R. The distribution of fitness effects among synonymous mutations in a gene under directional selection. eLife 8, e45952 (2019).
pubmed: 31322500 pmcid: 6692132 doi: 10.7554/eLife.45952
Eyre-Walker, A. & Keightley, P. D. The distribution of fitness effects of new mutations. Nat. Rev. Genet. 8, 610–618 (2007).
pubmed: 17637733 doi: 10.1038/nrg2146
Bozic, I. et al. Accumulation of driver and passenger mutations during tumor progression. Proc. Natl Acad. Sci. USA 107, 18545–18550 (2010).
pubmed: 20876136 pmcid: 2972991 doi: 10.1073/pnas.1010978107
Williams, M. J. et al. Measuring the distribution of fitness effects in somatic evolution by combining clonal dynamics with dN/dS ratios. eLife 9, e48714 (2020).
pubmed: 32223898 pmcid: 7105384 doi: 10.7554/eLife.48714
Turajlic, S., Sottoriva, A., Graham, T. & Swanton, C. Resolving genetic heterogeneity in cancer. Nat. Rev. Genet. 20, 404–416 (2019).
pubmed: 30918367 doi: 10.1038/s41576-019-0114-6
Venkatesan, S. et al. Induction of APOBEC3 exacerbates DNA replication stress and chromosomal instability in early breast and lung cancer evolution. Cancer Discov. 11, 2456–2473 (2021).
pubmed: 33947663 pmcid: 8487921 doi: 10.1158/2159-8290.CD-20-0725
Dewhurst, S. M. et al. Tolerance of whole-genome doubling propagates chromosomal instability and accelerates cancer genome evolution. Cancer Discov. 4, 175–185 (2014).
pubmed: 24436049 pmcid: 4293454 doi: 10.1158/2159-8290.CD-13-0285
Werner, B. et al. Measuring single cell divisions in human tissues from multi-region sequencing data. Nat. Commun. 11, 1035 (2020).
pubmed: 32098957 pmcid: 7042311 doi: 10.1038/s41467-020-14844-6
Del Monte, U. Does the cell number 10
pubmed: 19176997 doi: 10.4161/cc.8.3.7608
McGranahan, N. et al. Clonal status of actionable driver events and the timing of mutational processes in cancer evolution. Sci. Transl. Med. 7, 283ra54 (2015).
pubmed: 25877892 pmcid: 4636056 doi: 10.1126/scitranslmed.aaa1408
Berger, A. H. et al. High-throughput phenotyping of lung cancer somatic mutations. Cancer Cell 30, 214 (2016).
pubmed: 27478040 pmcid: 5003022 doi: 10.1016/j.ccell.2016.06.022
Lawson, A. R. J. et al. Extensive heterogeneity in somatic mutation and selection in the human bladder. Science 370, 75–82 (2020).
pubmed: 33004514 doi: 10.1126/science.aba8347
Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. 57, 289–300 (1995).
Watkins, T. B. K. et al. Pervasive chromosomal instability and karyotype order in tumour evolution. Nature 587, 126–132 (2020).
pubmed: 32879494 pmcid: 7611706 doi: 10.1038/s41586-020-2698-6
Frankell A. M., Colliver E., Mcgranahan N., Swanton C. cloneMap: a R package to visualise clonal heterogeneity. Preprint at bioRxiv https://doi.org/10.1101/2022.07.26.501523 (2022).

Auteurs

Maise Al Bakir (M)

Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.

Ariana Huebner (A)

Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Cancer Genome Evolution Research Group, Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.

Carlos Martínez-Ruiz (C)

Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Cancer Genome Evolution Research Group, Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.

Kristiana Grigoriadis (K)

Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Cancer Genome Evolution Research Group, Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.

Thomas B K Watkins (TBK)

Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.

Oriol Pich (O)

Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.

David A Moore (DA)

Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Department of Cellular Pathology, University College London Hospitals, London, UK.

Selvaraju Veeriah (S)

Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.

Sophia Ward (S)

Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Advanced Sequencing Facility, The Francis Crick Institute, London, UK.

Joanne Laycock (J)

Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.

Diana Johnson (D)

Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.

Andrew Rowan (A)

Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.

Maryam Razaq (M)

Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.

Mita Akther (M)

Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.

Cristina Naceur-Lombardelli (C)

Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.

Paulina Prymas (P)

Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.

Antonia Toncheva (A)

Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.

Sonya Hessey (S)

Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Cancer Metastasis Laboratory, University College London Cancer Institute, London, UK.
Computational Cancer Genomics Research Group, University College London Cancer Institute, London, UK.

Michelle Dietzen (M)

Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Cancer Genome Evolution Research Group, Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.

Emma Colliver (E)

Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.

Alexander M Frankell (AM)

Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.

Abigail Bunkum (A)

Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Cancer Metastasis Laboratory, University College London Cancer Institute, London, UK.
Computational Cancer Genomics Research Group, University College London Cancer Institute, London, UK.

Emilia L Lim (EL)

Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.

Takahiro Karasaki (T)

Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Cancer Metastasis Laboratory, University College London Cancer Institute, London, UK.

Christopher Abbosh (C)

Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.

Crispin T Hiley (CT)

Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.

Mark S Hill (MS)

Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.

Daniel E Cook (DE)

Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.

Gareth A Wilson (GA)

Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.

Roberto Salgado (R)

Department of Pathology, ZAS Hospitals, Antwerp, Belgium.
Division of Research, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

Emma Nye (E)

Experimental Histopathology, The Francis Crick Institute, London, UK.

Richard Kevin Stone (RK)

Experimental Histopathology, The Francis Crick Institute, London, UK.

Dean A Fennell (DA)

University of Leicester, Leicester, UK.
University Hospitals of Leicester NHS Trust, Leicester, UK.

Gillian Price (G)

Department of Medical Oncology, Aberdeen Royal Infirmary NHS Grampian, Aberdeen, UK.
University of Aberdeen, Aberdeen, UK.

Keith M Kerr (KM)

University of Aberdeen, Aberdeen, UK.
Department of Pathology, Aberdeen Royal Infirmary NHS Grampian, Aberdeen, UK.

Babu Naidu (B)

Birmingham Acute Care Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK.

Gary Middleton (G)

University Hospital Birmingham NHS Foundation Trust, Birmingham, UK.
Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.

Yvonne Summers (Y)

Division of Cancer Sciences, The University of Manchester and The Christie NHS Foundation Trust, Manchester, UK.

Colin R Lindsay (CR)

Division of Cancer Sciences, The University of Manchester and The Christie NHS Foundation Trust, Manchester, UK.

Fiona H Blackhall (FH)

Division of Cancer Sciences, The University of Manchester and The Christie NHS Foundation Trust, Manchester, UK.

Judith Cave (J)

Department of Oncology, University Hospital Southampton NHS Foundation Trust, Southampton, UK.

Kevin G Blyth (KG)

School of Cancer Sciences, University of Glasgow, Glasgow, UK.
Cancer Research UK Beatson Institute, Glasgow, UK.
Queen Elizabeth University Hospital, Glasgow, UK.

Arjun Nair (A)

Department of Radiology, University College London Hospitals, London, UK.
UCL Respiratory, Department of Medicine, University College London, London, UK.

Asia Ahmed (A)

Department of Radiology, University College London Hospitals, London, UK.

Magali N Taylor (MN)

Department of Radiology, University College London Hospitals, London, UK.

Alexander James Procter (AJ)

Department of Radiology, University College London Hospitals, London, UK.

Mary Falzon (M)

Department of Cellular Pathology, University College London Hospitals, London, UK.

David Lawrence (D)

Department of Thoracic Surgery, University College London Hospital NHS Trust, London, UK.

Neal Navani (N)

Lungs for Living Research Centre, UCL Respiratory, University College London, London, UK.
Department of Thoracic Medicine, University College London Hospitals, London, UK.

Ricky M Thakrar (RM)

Lungs for Living Research Centre, UCL Respiratory, University College London, London, UK.
Department of Thoracic Medicine, University College London Hospitals, London, UK.

Sam M Janes (SM)

Lungs for Living Research Centre, UCL Respiratory, University College London, London, UK.

Dionysis Papadatos-Pastos (D)

Department of Oncology, University College London Hospitals, London, UK.

Martin D Forster (MD)

Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Department of Oncology, University College London Hospitals, London, UK.

Siow Ming Lee (SM)

Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Department of Oncology, University College London Hospitals, London, UK.

Tanya Ahmad (T)

Department of Oncology, University College London Hospitals, London, UK.

Sergio A Quezada (SA)

Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Immune Regulation and Tumour Immunotherapy Group, Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.

Karl S Peggs (KS)

Department of Haematology, University College London Hospitals, London, UK.
Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.

Peter Van Loo (P)

Cancer Genomics Laboratory, The Francis Crick Institute, London, UK.
Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Caroline Dive (C)

Cancer Research UK Manchester Institute Cancer Biomarker Centre, University of Manchester, Manchester, UK.
Cancer Research UK Lung Cancer Centre of Excellence, University of Manchester, Manchester, UK.

Allan Hackshaw (A)

Cancer Research UK & UCL Cancer Trials Centre, London, UK.

Nicolai J Birkbak (NJ)

Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.
Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Bioinformatics Research Centre, Aarhus University, Aarhus, Denmark.

Simone Zaccaria (S)

Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Computational Cancer Genomics Research Group, University College London Cancer Institute, London, UK.

Mariam Jamal-Hanjani (M)

Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK. m.jamal-hanjani@ucl.ac.uk.
Cancer Metastasis Laboratory, University College London Cancer Institute, London, UK. m.jamal-hanjani@ucl.ac.uk.
Department of Oncology, University College London Hospitals, London, UK. m.jamal-hanjani@ucl.ac.uk.

Nicholas McGranahan (N)

Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK. nicholas.mcgranahan.10@ucl.ac.uk.
Cancer Genome Evolution Research Group, Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK. nicholas.mcgranahan.10@ucl.ac.uk.

Charles Swanton (C)

Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK. Charles.Swanton@crick.ac.uk.
Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK. Charles.Swanton@crick.ac.uk.
Department of Oncology, University College London Hospitals, London, UK. Charles.Swanton@crick.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH